Skip to content
Open in App
Adial Pharma logo

Adial Pharma

web2

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing experimental tre...

Symbol ยท ADIL
Company profile

About

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing experimental treatments for inflammatory diseases, with its lead program targeting ulcerative colitis following the acquisition of Azora Therapeutics. Its AT177 candidate is an oral, colon-targeted drug designed to activate the aryl hydrocarbon receptor locally in the intestine. The program remains in preclinical development, with human studies subject to regulatory authorization. Adial also retains AD04, a genetically targeted candidate for alcohol use disorder, but its regulatory filing states further development depends on dedicated partner or other funding. The company does not have an approved product and finances research through capital raising and other potential arrangements rather than medicine sales.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: ADIL
Expert coverage

Adial Pharma profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment